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Recurrent chromosomal deletions in cancer are typically thought to harbor tumor suppressors. In a recent
publication in Nature, Northcott and colleagues identify a novel region of structural variation in medulloblas-
toma that leads to oncogenic activation of GFI1B and GFI1 by repositioning these genes next to super-
enhancers.Genomic instability is one of the enabling
hallmarks of cancer and can lead to
extensive chromosomal abnormalities
(Hanahan and Weinberg, 2011). Sites of
recurrent genomic aberrations have long
been thought to harbor genes important
for tumor development; indeed, onco-
genes such asMYC and ERBB2 are found
in amplifications, the BCR-ABL fusion
gene results from a chromosomal trans-
location, and tumor suppressors such as
RB1, PTEN, and TP53 are frequently lost
in deleted regions.
Medulloblastoma is the most common
malignant pediatric brain tumor, with
large-scale genomic and transcriptomic
analyses identifying four distinct molecu-
lar subgroups (Taylor et al., 2012). North-
cott et al. (2014) recently analyzed
whole-genome sequencing of primary
group 3 and 4 medulloblastoma samples
for somatic structural variants (SVs).
Rather than limiting their search to recur-
rent amplifications or deletions, they
analyzed all chromosomal breakpoints
and identified a novel region of interest
spanning over 400 kb on chromosome
9q34.13. A single gene at this locus,
growth factor independence 1B (GFI1B),
was found to be overexpressed concom-
itant with proximal SV. Despite the variety
of observed SVs ranging from deletions
(Figure 1A), tandem duplication, and/or
inversions, these SVs resulted in reposi-
tioning GFI1B next to super-enhancers
(Figure 1). Additionally, after observing
mutually exclusive expression patterns
within group 3 tumors between GFI1B
and its paralog, growth factor indepen-
dence 1 (GFI1), the authors identified
thatGFI1was also subject to SV, similarly
varied between interchromosomal trans-160 Cancer Cell 26, August 11, 2014 ª2014 Elocations and tandem duplications
(Figure 1B). These also led to similar
displacement of GFI1 to regions adjacent
to other enhancers or super-enhancers
(Figure 1C).
Enhancers are short stretches of
genomic DNA that serve to bind activa-
tors and function in cis to drive transcrip-
tion of nearby genes (Ong and Corces,
2011). Recently, super-enhancers have
been identified as exceptionally large
euchromatic regions that serve as a
concentrated site of activator and tran-
scription factor binding and stimulate
higher transcriptional activity than typical
enhancers. While enhancers are highly
prevalent throughout the genome, su-
per-enhancers are scattered sparsely at
a few hundred sites, residing at key cell
identity genes, where they define cell
types by driving specific expression
patterns (Hnisz et al., 2013; Whyte et al.,
2013). Super-enhancers are also thought
to be dynamic, forming at essential onco-
genes during tumorigenesis, where they
remain exquisitely sensitive to bromodo-
main inhibition (Love´n et al., 2013).
This idea of dynamic super-enhancers
works in concert with data showing that
epigenetic heterogeneity and plasticity
play integral roles in the acquisition of
drug resistance in cancer (Sharma et al.,
2010). With a low somatic mutation rate
(0.52 per Mb) and frequent alteration of
chromatin modifiers across all subgroups
(Jones et al., 2012), medulloblastoma
may be the perfect candidate to observe
this phenomenon. Northcott et al. (2014),
however, describe ‘‘enhancer hijacking’’
as a mechanism in which genomic insta-
bility leads to the utilization of existing
epigenetic structure to drive oncogenelsevier Inc.expression. Thus, because epigenetic
plasticity represents a complementary
approach to the acquisition of somatic
mutations in the pathogenesis of cancer,
this study leads to intriguing questions
about the state of the epigenome in
medulloblastoma. Is the utiltization of
enhancer hijacking (rather than dynamic
generation of a new super-enhancer)
simply due to the enrichment of somatic
copy number aberrations in these sub-
groups (Northcott et al., 2012)? Are there
fundamental differences between medul-
loblastoma and other cancers that lead
to a relatively static epigenome in medul-
loblastoma, or are super-enhancers not
so readily plastic or dynamic?
Another question that remains to be
explored is whether there is an underlying
function within the GFI1 gene family that
promotes enhancer hijacking. GFI1 and
GFI1B are highly homologous transcrip-
tional repressors that are expressed in
the hematopoetic compartment and are
known proto-oncogenes in leukemia
and lymphoma. Because both GFI1 and
GFI1B are subjected to transcriptional
autoregulation and are able to repress
each other’s expression, does the under-
lying SV represent the only mechanism of
escape from a complex net of feedback
loops? Northcott et al. (2014) show that
GFI1/GFI1B cooperate with MYC to drive
medulloblastoma in an orthotopic xeno-
graft mouse model, despite the fact that
alone, neither was able to promote tumor-
igenesis in this model. Curiously, GFI1
activation, but not GFI1B, correlated
with MYC expression in medulloblas-
toma, whereas both cooperated with
MYC in this preclinical in vivo model.
Whether and how they cooperate to
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Figure 1. GFI1 and GFI1B Hijack Enhancers via Structural Variation
In medulloblastoma, GFI1B (as shown in A) and GFI1 (as shown in B) normally reside in heterochromatic
regions with little to no expression. Structural variation including deletions (A) or interchromosomal trans-
locations (B) can lead to juxtaposition of these genes next to enhancers or super-enhancers (as shown in
C), which drive oncogenic expression due to their increased concentrations of bound activators and
transcription factors (plotted in green and represented by circles and rectangles).
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Previewsmake a permissive environment for such
SV remains to be determined.
Each of the four medulloblastoma sub-
groups differs in age distribution, gender,
and outcome. Two of these subgroups
(groups 1 and 2) are driven predominantly
by a single prominent signaling pathway(WNT or SHH), while group 3 and group
4 tumors show more complex genetics
and signaling. Group 3 tumors generally
have the poorest prognosis, and by
identifying these super-enhancer acti-
vated oncogenes, the authors identify a
possible therapeutic avenue using bro-Cancer Cell 26modomain inhibitors. Furthermore, this
study was successful in identifying onco-
genes at regions containing, in part,
common deletions. Despite knowing for
15 years that translocations in Burkitt’s
lymphoma can lead to activation of
MYC by juxtaposing it next to the IGl
enhancer, the current paradigm still
focuses on the assumption that the type
of SV defines the function of the gene of
interest: gains representing oncogenic
loci and losses representing tumor sup-
pressor loci. While large efforts have
been spent to identify tumor suppressors
in commonly deleted regions, Northcott
and colleagues ask us to rethink these
strategies for tumors where SVs have
clearly delineated and recurrent break-
points, especially if studies to date have
not yielded strong candidates.REFERENCES
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